[Federal Register Volume 84, Number 93 (Tuesday, May 14, 2019)]
[Notices]
[Pages 21347-21348]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-09920]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Announcement of Meeting of the National Clinical Care Commission

AGENCY: Office of Disease Prevention and Health Promotion, Office of 
the Assistant Secretary for Health, Office of the Secretary, Department 
of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Clinical Care Commission (the Commission) will

[[Page 21348]]

conduct its third meeting on June 27, 2019. The Commission will 
evaluate and make recommendations to the U.S. Department of Health and 
Human Services (HHS) Secretary and Congress regarding improvements to 
the coordination and leveraging of federal programs related to 
awareness and clinical care for complex metabolic or autoimmune 
diseases that result from issues related to insulin that represent a 
significant disease burden in the United States, which may include 
complications due to such diseases.

DATES: The meeting will take place on June 27, 2019 from 8:00 a.m. to 
approximately 5:00 p.m. Eastern Time (ET).

ADDRESSES: National Institutes of Health, Building 35, John Edward 
Porter Neuroscience Research Center [PNRC II], 35 Convent Drive, 
Bethesda, MD 20892. The meeting will also be held online via webcast. 
To register to attend the meeting, please visit the registration 
website at https://events.kauffmaninc.com/events/nccc3/index.cfm.

FOR FURTHER INFORMATION CONTACT: Clydette Powell, Designated Federal 
Officer, National Clinical Care Commission, U.S. Department of Health 
and Human Services, Office of the Assistant Secretary for Health, 
Office of Disease Prevention and Health Promotion, 1101 Wootton 
Parkway, Suite LL-100, Rockville, MD 20852. Email: [email protected]. 
Additional information may be obtained at https://health.gov/hcq/national-clinical-care-commission.asp.

SUPPLEMENTARY INFORMATION: The National Clinical Care Commission Act 
(Pub. L. 115-80) requires the HHS Secretary to establish the National 
Clinical Care Commission. The Commission will consist of 
representatives of specific federal agencies and non-federal 
individuals and entities who represent diverse disciplines and views. 
The Commission will evaluate and make recommendations to the HHS 
Secretary and Congress regarding improvements to the coordination and 
leveraging of federal programs related to awareness and clinical care 
for complex metabolic or autoimmune diseases that result from issues 
related to insulin that represent a significant disease burden in the 
United States, which may include complications due to such diseases.
    This third meeting of the Commission will consist of presentations 
by its four subcommittees on their work to support the call for 
information about federal diabetes programs. The Commission members 
will discuss the work of the subcommittees and overall plan to collect 
information relevant to its charge. The names and biographies of the 
Commission members and final meeting agenda will be available prior to 
the meeting at https://health.gov/hcq/national-clinical-care-commission.asp.
    Public Participation at Meeting: The Commission invites public 
comment on issues related to the Commission's charge either in-person 
at the meeting or in writing. In-person attendees who plan to provide 
oral comments at the Commission meeting during a designated time must 
submit their comments to [email protected] on or before June 12, 2019 and 
must check-in on-site. To accommodate as many individuals as possible, 
the time for each comment will be limited to three minutes. If more 
requests are received than can be accommodated, speakers will be 
randomly selected. The nature of the comments will not be considered in 
making this selection. Written comments are welcome throughout the 
entire development process of the Commission and may be emailed to 
[email protected], or by mail to the following address: Public Commentary, 
National Clinical Care Commission, 1101 Wootton Parkway, Suite LL-100, 
Rockville, MD 20852. Written comments should not exceed three pages in 
length.
    To attend the Commission meeting, individuals must pre-register at 
the registration website at https://events.kauffmaninc.com/events/nccc3/index.cfm. In-person and live webcast attendance options are 
available. In-person attendance at the meeting is limited to space 
available. In-person registrations will be accepted until maximum 
capacity is reached and must be completed by June 20, 2019. On the day 
of the meeting, seating will be provided first to persons who have pre-
registered. Those who have not pre-registered will be accommodated on a 
first come, first served basis if additional seats are still available 
10 minutes before the meeting starts. Individuals who need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should indicate the special accommodation when 
registering online or by notifying Jennifer Gillissen at 
[email protected] by June 20, 2019.
    Authority: The National Clinical Care Commission is required under 
the National Clinical Care Commission Act (Pub. L. 115-80). The 
Commission is governed by provisions of the Federal Advisory Committee 
Act (FACA), Public Law 92-463, as amended (5 U.S.C., App.) which sets 
forth standards for the formation and use of federal advisory 
committees.

    Dated: May 2, 2019.
Donald Wright,
Deputy Assistant Secretary for Health.
[FR Doc. 2019-09920 Filed 5-13-19; 8:45 am]
 BILLING CODE 4150-32-P